This global educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat patients with CLL/SLL and MCL.
The goal of this program is to improve the knowledge, competence, and performance of learners in selecting the optimal BTKi-based regimens for patients with CLL/SLL and MCL.
Upon completion of this activity, participants should be able to:
Evaluate differences between covalent and noncovalent BTKis in terms of molecular characteristics, selectivity, clinical data, approved indications, dosing, safety profiles, and efficacy and their respective impact on clinical practice
Plan BTKi-based therapeutic strategies for patients with CLL/SLL or MCL, taking into consideration global indications, regional/national expert recommendations, and recent practice-changing clinical trial results
Select an optimal sequence of targeted therapies for patients with resistance to or intolerance of covalent BTKi-based therapy to optimize clinical outcomes
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Brad Kahl, MD
Professor of Medicine
Washington University School of Medicine
Director Lymphoma Program
Siteman Cancer Center
St. Louis, Missouri
Brad S. Kahl, MD: consultant/advisor/speaker: AbbVie, ADCT, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Incyte, Janssen, Kite, Lilly, Novartis, Roche, Seattle Genetics.
Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Toby Eyre, MBCHB, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Autolus, Beigene, Incyte, Janssen, Kite/Gilead, Lilly, Roche, Secura Bio; researcher: AstraZeneca, Beigene.
Pier Luigi Zinzani, MD, PhD
Professor of Hematology
Head of Lymphoma and Chronic Lymphoproliferative Syndromes Unit
Institute of Hematology “L. e A. Seràgnoli”
University of Bologna
Pier Luigi Zinzani, MD, PhD: consultant/advisor/speaker: AbbVie, BeiGene, Bristol-Myers Squib, Incyte, Janssen, Kite/Gilead, Kyowa Kirin, Lilly, Merck, Novartis, Recordati, Regeneron, Roche, SOBI, Takeda.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 26, 2024, through January 25, 2025:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.